What is the recent rebranding by Bio-Techne related to stock symbol TECH?

Bio-Techne rebranded its B-MoGen Biotechnologies portfolio as R&D Systems on September 21, 2020.

Bio-Techne Rebrands B-MoGen Biotechnologies As Part Of The R&D Systems Product Portfolio

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) announced the rebranding of its B-MoGen Biotechnologies portfolio to R&D Systems on September 21, 2020. This change includes the retirement of the B-MoGen website, with all products and services now accessible through R&D Systems' site. President Dave Eansor highlighted that this consolidation aims to enhance service offerings for cell and gene therapy customers, providing value-added services alongside high-quality products. More details on the TcBuster gene transfer system can be found on their new site.

Positive

Consolidation of B-MoGen into R&D Systems enhances service offerings.
Streamlined access to legacy products through a single platform.

Negative

None.

Argus Session date unavailable

-2.54% session move Open Argus

Details

News Market Reaction – TECH

The recorded move for TECH in the trading session of this news was -2.54%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

09/21/2020 - 07:00 AM EDT

MINNEAPOLIS, Sept. 21, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that the B-MoGen Biotechnologies portfolio of genome engineering services, GMP therapeutic manufacturing services, and its proprietary transposon-transposase gene transfer system, TcBuster™, will be rebranded as R&D Systems. As part of the rebranding, the B-MoGen Biotechnologies website will be retired. Service details and purchasing options will be maintained through the R&D Systems website. Currently all legacy B-MoGen products and services can be purchased through R&D Systems.

Dave Eansor, President of Bio-Techne's Protein Sciences Segment, commented, "We are excited to consolidate the B-MoGen portfolio within R&D Systems' extended offering of discovery-to-clinic cell and gene therapy solutions. Cell and gene therapy customers are looking for value-added services to complement the high-quality products that they purchase from R&D systems. With this consolidation, we can meet the needs of our customers in new and dynamic ways."

More information on the TcBuster and other legacy B-MoGen Biotechnologies services can be found at www.rndsystems.com/products/genome-engineering

About Bio-Techne Corporation (NASDAQ: TECH)